XBI the ETF for Biotechnology LONG

Biotechnology is expected to be a hot subsector this year as healthcare recovered further from

the COVID pandemic anything from startups to big pharma- from vaccines to new drugs for

diabetes, liver disease and obesity. This is shown on a weekly chart to show the long term trend

with XBI pivoting to bullish back in early November. I add long positions when I see a dip

on the 3-4hr chart. My targets are the fib retracement expectation at 116 confluent with

the first upper VWAP band line and then the 135-138 zone underneath the second upper line

shown in thin red on the chart. This ETF smooths out the volatility characteristic of some

of the smaller biotechnology firms making it safer albeit with lesser rewards expectations.

Positions in NVAX and MRNA are having a good start to the week and will reflect in a small

way in this ETF which has broad constituent stocks within its portfolio.

Comment:

Nice gain to begin the week. Will close 5% of the position to be deployed
into a long-term call option into 2026 on NVAX which is reporting and
recently settled a litigation matter that weighed it down for a long
time. Will add back to XBI position when the price settles down
to the liquidity-adjusted moving average.

Trade active:

XBI is trading well with a good gain so far this week. 5% of position of a lot of call options closed- these options are spread across time. the ones expiring at the March monthly are trimmed. Profits will be deployed into call options out of the money
in 2026 on NVAX.

Trade active:

XBI up 5% for the week with lots of volatility along the way. I am daytrading the volatility to get daily profits to fund buying additional call options expiring 4-6 months out.

Comment:

Updated chart showing consolidation range right now

Comment:

Price is on support- i will buy next Monday a good sized add after the 3 day weekend.